Other Clinical Trial - Cereset Research Exploratory Study

Status Recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the use of Cereset Research to improve autonomic function in participants with symptoms of stress, anxiety, or insomnia.

Clinical Trial Description

The primary objective of this open label exploratory study is to evaluate the effect of CR to improve autonomic cardiovascular regulation in participants with symptoms of stress, anxiety, or insomnia. The secondary objective is to evaluate the effect of CR on a variety of self-reported symptom inventories. Tertiary objectives are to explore the impact of selected medications on outcomes associated with use of CR, the effect size in subgroups of participants who also report specific co-morbid symptoms or conditions of interest, and any unexpected challenges or barriers for working with the same. The latter includes those with TBI, PTSD, hypertension, hot flashes, chronic pain, or prior stroke. Methods: This will be a single site, open label, pilot clinical trial, enrolling people aged 11 or older, who have self-reported symptoms of stress, anxiety, or insomnia, and meet a threshold score on self-reported inventories. Up to 150 participants will be enrolled. Participants will receive between 6 and 12 sessions of audible tones echoing current brainwave activity (CR). Participants will continue their other current care throughout the study. There will be pre- and post-intervention data collection of physiological outcomes (BP, HR, and measures of autonomic cardiovascular regulation assessed by heart rate variability and baroreflex sensitivity), which will alse serve as the primary outcome. Secondary outcomes to be collected include symptom inventories for insomnia (Insomnia Severity Index, ISI; Pittsburgh Sleep Quality Index, PSQI), depression (Center for Epidemiological Studies- Depression Scale, CES-D), anxiety (Generalized Anxiety Disorder-7, GAD-7), stress (Perceived Stress Scale, PSS), traumatic stress (PTSD Checklist for civilians, PCL-C, or military, PCL-M), , and overall quality of life (QOLS). Other secondary outcome inventories will be collected for physical activity (International Physical Activity Questionnaire, IPAQ-SF), and physical activity satisfaction questions, as well. Participants who also self-report having specific co-morbid symptoms or conditions of interest may complete additional condition-specific outcome measures. All measures will be collected at an enrollment visit (V1), and the intervention will begin 0-14 days thereafter. Mean contrasts will be used to compare the changes in measures of autonomic cardiovascular regulation from V1 to V3, the primary outcome, as well as for secondary outcomes. Linear mixed models, which can accommodate within-subject correlations due to repeated assessments over time, will be used to generate point estimates for effect size along with 95% confidence intervals. ;

Study Design

Related Conditions & MeSH terms

Cardiovascular Conditions After Birth
Disease
Nervous System Diseases
Neurological Diseases or Conditions
Psychophysiologic Disorders

Clinical Trial Details

NCT number	NCT03777267
Study type	Interventional
Source	Wake Forest University Health Sciences
Contact	Study Coordinator
Phone	336-716-9447
Email	wfhirrem@wakehealth.edu
Status	Recruiting
Phase	N/A
Start date	April 12, 2019
Completion date	January 2026

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03128086` - Weaning From Mechanical Ventilation in Neurological Patients	N/A
Recruiting	`NCT04581577` - Perceptions of the Clinical and Psychosocial Impact of Covid-19 in Patients With Neuromuscular and Neurological Disorders
Active, not recruiting	`NCT05742087` - Neuropathy and Anti-GFAP Antibodies
Recruiting	`NCT05645003` - Transcranial Magnetic Stimulation Therapy in Neuropathic Painful Spinal Cord Injury Patients	N/A
Withdrawn	`NCT04377425` - COVID-19 Prevalence and Cognitive Deficits in Neurological Patients
Withdrawn	`NCT01898975` - A Gray Zone Approach to Stroke Volume Variation Derived From NICOM	N/A
Active, not recruiting	`NCT03480581` - Impact of Reverse vs. Forward ICARE Training Interventions	N/A
Completed	`NCT04061616` - Transcultural Validation of the Physical Activity Scale for Individuals With Physical Disabilities (PASIPD) in French: The PASIPD-Fr	N/A
Recruiting	`NCT04706481` - Archival of Human Biological Samples in CU-Med Biobank
Completed	`NCT05169788` - Rehabilitation Through the Italian Version of the Teen Online Problem-Solving (TOPS) Program	N/A
Completed	`NCT03619642` - Reliability, Validity and Clinical Utility of a Robotic Assessment for Proprioception	N/A
Recruiting	`NCT05526508` - Rebound Exercise in Neurological Disorders	N/A
Recruiting	`NCT05086380` - Modulation of Sense of Agency With Non-invasive Brain Stimulation and Mindfulness-based Stress Reduction Therapy	N/A
Recruiting	`NCT04866251` - Prevalence of Gag Reflex in Healthy Persons and Across Different Patient Groups and Its Relevance in Dysphagia Screening	N/A
Not yet recruiting	`NCT05796037` - An Observational Study of Patients Living With Chronic Neurological Diseases
Completed	`NCT05097066` - Patterns and Outcomes of Neurosurgery in England Over a Five-year Period

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.